DK0808172T3 - Kombinationer af angiotensinkonverterende enzyminhibitor og bivirkningsreducerende mængde af aldesteronantagonist - Google Patents
Kombinationer af angiotensinkonverterende enzyminhibitor og bivirkningsreducerende mængde af aldesteronantagonistInfo
- Publication number
- DK0808172T3 DK0808172T3 DK96910309T DK96910309T DK0808172T3 DK 0808172 T3 DK0808172 T3 DK 0808172T3 DK 96910309 T DK96910309 T DK 96910309T DK 96910309 T DK96910309 T DK 96910309T DK 0808172 T3 DK0808172 T3 DK 0808172T3
- Authority
- DK
- Denmark
- Prior art keywords
- antagonist
- combinations
- aldesterone
- side effect
- converting enzyme
- Prior art date
Links
- 239000005541 ACE inhibitor Substances 0.000 title abstract 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 title abstract 2
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 title 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 108010061435 Enalapril Proteins 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 208000002682 Hyperkalemia Diseases 0.000 abstract 1
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 abstract 1
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 abstract 1
- 229940083712 aldosterone antagonist Drugs 0.000 abstract 1
- 239000002170 aldosterone antagonist Substances 0.000 abstract 1
- 229960000830 captopril Drugs 0.000 abstract 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 abstract 1
- 238000011262 co‐therapy Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229960000873 enalapril Drugs 0.000 abstract 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229960002256 spironolactone Drugs 0.000 abstract 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Furan Compounds (AREA)
- Steroid Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38685295A | 1995-02-10 | 1995-02-10 | |
| PCT/US1996/001969 WO1996024373A2 (en) | 1995-02-10 | 1996-02-09 | Combination of angiotensin converting enzyme inhibitor and side-effect-reduced amount of aldosterone antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0808172T3 true DK0808172T3 (da) | 2003-10-20 |
Family
ID=23527334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK96910309T DK0808172T3 (da) | 1995-02-10 | 1996-02-09 | Kombinationer af angiotensinkonverterende enzyminhibitor og bivirkningsreducerende mængde af aldesteronantagonist |
Country Status (13)
| Country | Link |
|---|---|
| EP (2) | EP1136078A3 (da) |
| JP (1) | JPH11507012A (da) |
| KR (1) | KR19980702099A (da) |
| AT (1) | ATE243529T1 (da) |
| AU (1) | AU5354196A (da) |
| BR (1) | BR9604882A (da) |
| CA (1) | CA2212713A1 (da) |
| DE (1) | DE69628821T2 (da) |
| DK (1) | DK0808172T3 (da) |
| ES (1) | ES2205023T3 (da) |
| NZ (1) | NZ305528A (da) |
| PT (1) | PT808172E (da) |
| WO (1) | WO1996024373A2 (da) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010033473A (ko) * | 1997-12-23 | 2001-04-25 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | Ａｃｅ 저해제-ｍｍｐ 저해제의 병용 제제 |
| US7417038B1 (en) | 1998-10-15 | 2008-08-26 | Imperial Innovations Limited | Methods of treating cachexia |
| EP1126880A2 (en) | 1998-11-06 | 2001-08-29 | G.D. SEARLE & CO. | Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease |
| SE9903028D0 (sv) * | 1999-08-27 | 1999-08-27 | Astra Ab | New use |
| MXPA02001694A (es) | 1999-08-30 | 2002-08-06 | Aventis Pharma Gmbh | Uso de inhibidores del sistema renina-angiotensina en la prevencion de eventos cardiovasculares. |
| WO2001080895A2 (en) * | 2000-04-26 | 2001-11-01 | First Horizon Pharmaceutical Corporation | Methods and compositions for the treatment of cardiac indications |
| US20050014732A1 (en) * | 2003-03-14 | 2005-01-20 | Pharmacia Corporation | Combination of an aldosterone receptor antagonist and an anti-diabetic agent |
| CL2004000544A1 (es) * | 2003-03-18 | 2005-01-28 | Pharmacia Corp Sa Organizada B | Uso de una combinacion farmaceutica, de un antagonista del receptor de aldosterona y un inhibidor de endopeptidasa neutral, util para el tratamiento y prevencion de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopati |
| BRPI0715126B8 (pt) * | 2006-08-04 | 2021-07-27 | Medizinische Hochschule Hannover | métodos para avaliação do risco de intervenções cardíacas e usos à base de gdf-15 |
| FR2917975B1 (fr) | 2007-06-26 | 2009-10-16 | Ceva Sante Animale Sa | Compositions et traitement de l'insuffisance cardiaque chez les animaux mammiferes non humains |
| CN102421433B (zh) * | 2009-03-26 | 2015-09-23 | 阿贾伊·古普塔 | 用于治疗肾病的组合物和方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4217347A (en) * | 1977-12-27 | 1980-08-12 | E. R. Squibb & Sons, Inc. | Method of treating hypertension and medicaments therefor |
| AU7854094A (en) * | 1993-10-04 | 1995-05-01 | Handforth Investments Ltd. | Use of amiodarone for the treatment of heart failure |
-
1996
- 1996-02-09 JP JP8524487A patent/JPH11507012A/ja not_active Abandoned
- 1996-02-09 WO PCT/US1996/001969 patent/WO1996024373A2/en not_active Ceased
- 1996-02-09 ES ES96910309T patent/ES2205023T3/es not_active Expired - Lifetime
- 1996-02-09 EP EP01116593A patent/EP1136078A3/en not_active Withdrawn
- 1996-02-09 DK DK96910309T patent/DK0808172T3/da active
- 1996-02-09 AT AT96910309T patent/ATE243529T1/de not_active IP Right Cessation
- 1996-02-09 NZ NZ305528A patent/NZ305528A/en unknown
- 1996-02-09 BR BR9604882A patent/BR9604882A/pt not_active Application Discontinuation
- 1996-02-09 EP EP96910309A patent/EP0808172B1/en not_active Expired - Lifetime
- 1996-02-09 DE DE69628821T patent/DE69628821T2/de not_active Expired - Fee Related
- 1996-02-09 PT PT96910309T patent/PT808172E/pt unknown
- 1996-02-09 AU AU53541/96A patent/AU5354196A/en not_active Abandoned
- 1996-02-09 CA CA002212713A patent/CA2212713A1/en not_active Abandoned
- 1996-02-09 KR KR1019970705494A patent/KR19980702099A/ko not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP0808172B1 (en) | 2003-06-25 |
| ATE243529T1 (de) | 2003-07-15 |
| PT808172E (pt) | 2003-11-28 |
| EP1136078A3 (en) | 2002-07-24 |
| AU5354196A (en) | 1996-08-27 |
| NZ305528A (en) | 2001-05-25 |
| DE69628821D1 (de) | 2003-07-31 |
| BR9604882A (pt) | 1998-05-19 |
| CA2212713A1 (en) | 1996-08-15 |
| EP1136078A2 (en) | 2001-09-26 |
| WO1996024373A3 (en) | 1996-09-26 |
| WO1996024373A2 (en) | 1996-08-15 |
| EP0808172A2 (en) | 1997-11-26 |
| ES2205023T3 (es) | 2004-05-01 |
| KR19980702099A (ko) | 1998-07-15 |
| JPH11507012A (ja) | 1999-06-22 |
| DE69628821T2 (de) | 2004-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69533058D1 (de) | Speicherplattenanordnung mit redundanter Speicherung und Verfahren zur inkrementalen Redundanzerzeugung während des Datenschreibens auf die Speicherplattenanordnung | |
| BR9915134A (pt) | Co-terapia e terapia combinada para o tratamento de distúrbio cardiovascular em um indivìduo, e, composição | |
| DK0808172T3 (da) | Kombinationer af angiotensinkonverterende enzyminhibitor og bivirkningsreducerende mængde af aldesteronantagonist | |
| MXPA05000832A (es) | Metodos de diagnosticar y tratar pre-eclampsia o eclampsia. | |
| NZ310730A (en) | Epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of congestive heart failure | |
| WO2004030627A3 (en) | Synergistic methods and compositions for treating cancer | |
| DE19875040I2 (de) | Phosphinylalkanoyl-substituierte Proline | |
| SG155054A1 (en) | Human anti- neutralizing antibodies as selective pathway inhibitors | |
| MY121008A (en) | Combination therapy comprising atorvastatin and an antihypertensive agent. | |
| MY114347A (en) | Synergistic therapeutic compositions and methods. | |
| EP1059100A3 (en) | Combinations of CRF antagonists and renin-angiotensin system inhibitors | |
| EP0220107A3 (en) | Use of angiotensin-converting enzyme inhibitors in macular degeneration | |
| DK1429756T3 (da) | Behandling af xanthoma med azetidinonderivater som sterolabsorptionsinhibitorer | |
| MXPA01009035A (es) | Terapia de combinacion de inhibidor de enzima convertidora de angiotensina y antagonista de aldosterona epoxi-esteroidea para tratamiento de enfermedad cardiovascular. | |
| TR199901703T2 (xx) | Siklooksijenaz-2 inhibit�rlerini anti-anjiyojenik ajanlar olarak kullanma y�ntemi. | |
| WO2003075953A3 (en) | Immunomodulatory polymeric antigens for treating inflammatory pathogies | |
| IS5101A (is) | Aðferðir við inngjöf efnasambanda sem eru mótefnigegn CD40L í sambandi við læknismeðferð | |
| TR199801988T2 (xx) | Kalp yetmezli�inin endotelin antagonistleri ile tedavisi i�in y�ntem. | |
| ATE236653T1 (de) | Kombination in feste dosiermenge von angiotensin- converting-enzyme-hemmern mit calcium-kanal antagonisten zur behandlung von herz- kreislauferkrankungen | |
| WO2002009759A3 (en) | Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders | |
| WO1996024372A3 (en) | Combination of angiotensin converting enzyme inhibitor, side-effect-reduced amount of aldosterone antagonist and diuretic | |
| EP1549141A4 (en) | METHOD AND COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE DISEASES USING CLOFARABIN | |
| PL373391A1 (en) | Aldosterone blocker therapy to prevent or treat inflammation-related disorders | |
| WO2001046405A3 (en) | Modulation of pax-2 for controlled apoptosis or survival of cells | |
| EA200100385A1 (ru) | Композиция и способ лечения нарушения гемостаза у субъекта (варианты) |